Skip to content

Guidelines

TL;DR — The 2022 ACC/AHA Aortic Disease Guideline (Isselbacher et al., Circulation) is the anchor document: 5.5 cm remains the Class 1 sporadic root/ascending threshold, but 2022's real innovations are (i) 5.0 cm as a 2a option when surgery is done by experienced surgeons in a "Multidisciplinary Aortic Team" at a high-volume center (≥30–40 aortic procedures/yr), (ii) formal adoption of body-size-indexed criteria (area/height ≥10 cm²/m at 2a; ASI ≥3.08 or AHI ≥3.21 cm/m at 2b), (iii) a tightened growth criterion (≥0.3 cm/yr ×2 yr, Class 1), and (iv) genotype-stratified thresholds for heritable disease. The striking structural fact: essentially every operative-threshold recommendation carries LOE B-NR or C — observational or expert-opinion evidence — while the rare LOE A items in the thoracic sections are Marfan medical therapy (beta-blocker or ARB), CSF drainage for open TAAA repair, and cold renal perfusion during open TAAA repair. Europe's 2024 EACTS/STS guideline reframes the aorta as an "organ" and — verified below from the retrieved full text — diverges from ACC/AHA on substance: risk-factor-modified 50-mm thresholds without a formal team gate, ascending length >11 cm adopted as a formal risk factor (IIa B), and a diameter hinge point re-read at 52.5 mm. Where documents and eras disagree — 5.0 vs 5.5, indexed vs absolute size, length, women, exercise — the disagreement is itself the map of what remains unknown.

The document landscape

Guideline Citation Status
2022 ACC/AHA Aortic Disease Guideline Isselbacher EM, et al. Circulation. 2022;146:e334-e482 (PMID 36322642); co-published in JACC (PMID 36334952) Current US standard; replaces 2010
2010 ACCF/AHA Thoracic Aortic Disease Guideline Hiratzka LF, et al. Circulation. 2010;121:e266-e369 (PMID 20233780) Superseded; origin of much current practice
2014 ESC Aortic Diseases Guideline Erbel R, et al. Eur Heart J. 2014;35:2873-2926 (PMID 25173340) European reference of the 2014–2024 era
2024 EACTS/STS Guideline on the "aortic organ" Czerny M, et al. Eur J Cardiothorac Surg. 2024;65(2):ezad426 (PMID 38408364); co-published Ann Thorac Surg. 2024;118:5-115 (PMID 38416090); clinical-cases companion (PMID 39196761) Current joint European/US surgical document
ASE/EACVI multimodality imaging document (2015) Goldstein SA, et al. J Am Soc Echocardiogr. 2015;28:119-182 (PMID 25623219) Imaging technique standard

2022 ACC/AHA: key thresholds (with Class of Recommendation / Level of Evidence)

All rows below were extracted from the guideline's recommendation tables (Isselbacher 2022, PMID 36322642).

Sporadic aneurysm of the aortic root / ascending aorta

Trigger COR LOE
Symptoms attributable to the aneurysm 1 C-LD
Maximum diameter ≥5.5 cm (asymptomatic) 1 B-NR
Growth ≥0.3 cm/yr in 2 consecutive years or ≥0.5 cm in 1 year (tomographically confirmed) 1 C-LD
≥5.0 cm, surgery by experienced surgeons in a Multidisciplinary Aortic Team 2a B-NR
Cross-sectional area/height ratio ≥10 cm²/m (height >1 SD from mean; experienced MAT) 2a C-LD
ASI ≥3.08 cm/m² or AHI ≥3.21 cm/m (experienced MAT) 2b C-LD

Genetic and familial disease

Population Trigger COR LOE
Marfan syndrome Root ≥5.0 cm 1 B-NR
Marfan Root ≥4.5 cm + features of increased dissection risk (e.g., rapid growth ≥0.3 cm/yr, family history of dissection, desire for pregnancy) 2a B-NR
Marfan Cross-sectional root area/height ≥10 cm²/m 2a C-LD
Marfan Diameter approaching threshold, VSRR candidate, very low surgical risk (experienced MAT) 2b C-LD
Marfan Nondissected arch/descending/abdominal aneurysm ≥5.0 cm 2a C-EO
Loeys-Dietz (pathogenic variants in the LDS genes) Intact arch/descending/abdominal aorta ≥4.5 cm, modulated by specific variant, age, growth, family history 2b C-EO
Nonsyndromic heritable TAD, no identified variant, no family diameter data, no high-risk features Root/ascending ≥5.0 cm 1 C-LD
Same, but relative dissected at <5.0 cm, or high-risk features, or undergoing cardiac surgery for other indications ≥4.5 cm (experienced MAT) 2a C-LD
Turner syndrome ≥15 yr ASI ≥2.5 cm/m² + dissection risk factors → surgery reasonable; without risk factors → may be considered 2a / 2b C-LD / C-EO

The guideline also tabulates gene-by-gene thresholds for HTAD; the retrieved narrative confirms the five covered nsHTAD genes (ACTA2, PRKG1, MYH11, MYLK, LOX — named in the section heading), dissection below conventional thresholds for several of them, and gene-informed management (Isselbacher 2022, PMID 36322642). The per-gene numeric thresholds themselves are still not reproduced here: both retrievable full-text renderings (Circulation via PMC9876736 and the JACC co-publication via PMC9860464) strip the italicized gene symbols from body text and omit the tables, and the publisher sites could not be retrieved this session [unverified at gene-level granularity]. The 2024 EACTS/STS per-gene thresholds, by contrast, are verified below. See genetics-of-taa.

Bicuspid aortic valve

Trigger COR LOE
Root or ascending diameter ≥5.5 cm 1 B-NR
Cross-sectional area/height ≥10 cm²/m (experienced MAT) 2a B-NR
5.0–5.4 cm + additional dissection risk factor (family history of dissection; growth ≥0.3 cm/yr) (experienced MAT) 2a B-NR
Root/ascending ≥4.5 cm at the time of surgical aortic valve repair/replacement → concomitant replacement reasonable (experienced MAT); supportive text individualizes (long life expectancy/low risk/root phenotype favor it; higher-risk AS patients may not warrant it) 2a B-NR
TTE screening of all first-degree relatives 2a B-NR

Full BAV context: bicuspid-aortopathy.

Descending aorta, arch, and teams

Item COR LOE
Intact descending TAA ≥5.5 cm → repair 1 B-NR
Descending <5.5 cm with rupture risk factors (growth ≥0.5 cm/yr, symptoms, CTD/HTAD, saccular morphology, female sex, infection) → repair may be considered 2b B-NR
Non-syndromic descending TAA meeting criteria + suitable anatomy → TEVAR over open 1 B-NR
Unsuitable anatomy → open repair reasonable 2a B-NR
Ruptured descending TAA, anatomic candidate → TEVAR over open 1 B-NR
CSF drainage in open TAAA at high spinal-cord-injury risk 1 A
Hemiarch extension when aneurysm involves proximal arch 2a C-LD
Elephant trunk when arch aneurysm extends into proximal descending 2b C-LD
Urgent aortic disease decided by multidisciplinary team 1 C-EO
Referral to high-volume center (≥30–40 aortic procedures/yr) with experienced MAT for extensive/complex/comorbid cases 2a C-LD

Medical therapy and lifestyle (selected)

Item COR LOE
Marfan: beta-blocker or ARB at maximally tolerated dose 1 A
Marfan: both classes together 2a C-LD
Sporadic TAA: antihypertensives if BP ≥130/80 1 B-NR
Sporadic TAA: beta-blocker to BP goal; ARB adjunct 2a C-LD / C-EO
Avoid intense isometric exercise (heavy weightlifting/Valsalva), burst exertion, collision sports 1 C-EO
Surveillance: TTE at diagnosis (1, C-LD); CT/MRI at diagnosis (2a); re-image 6–12 mo, then every 6–24 mo (2a); post-TEVAR CT 1 mo/12 mo/annual (1, B-NR); post-open CT/MRI at 1 yr then q5y (2a) — —

Details and trial evidence: medical-therapy, imaging-and-surveillance.

The evidence-level anatomy of the guideline

Read the LOE column: every size-threshold recommendation above — including the flagship 5.5 cm Class 1 — is B-NR (nonrandomized) or C (limited data/expert opinion). The 5.5 cm criterion traces to natural-history cohorts "without centerline analysis" and an assumed elective mortality <5% (Isselbacher 2022, PMID 36322642; Coady 1997, PMID 9081092; Davies 2002, PMID 11834007). The conspicuous LOE A items in the thoracic sections are Marfan medical therapy (built on the randomized trials and IPD meta-analysis; Pitcher 2022, PMID 36049495), CSF drainage for open TAAA (Coselli 2002 RCT, PMID 11932655), and cold blood/crystalloid renal perfusion during open TAAA repair involving the renal arteries (Isselbacher 2022, PMID 36322642). In other words: the decisions with the largest stakes (when to open a chest prophylactically) rest on observational data, and the one domain with RCTs (Marfan pharmacotherapy) produced only surrogate-endpoint effects. The first RCT aimed at a surgical threshold (TITAN:SvS, 5.0–5.4 cm surgery vs surveillance; NCT03536312) is acknowledged by the guideline as potentially decision-changing and is still enrolling (Isselbacher 2022, PMID 36322642).

What changed in 2022 (vs 2010 ACC/AHA and 2014 ESC)

Verifiable from the 2022 document itself (Isselbacher 2022, PMID 36322642), which updates the 2010 thoracic guideline (Hiratzka 2010, PMID 20233780) and sits alongside the 2014 ESC document (Erbel 2014, PMID 25173340):

  • Institutional volume and the Multidisciplinary Aortic Team are new organizing concepts, with the ≥30–40 procedures/yr definition drawn from volume-outcome data (Hughes 2013, PMID 22306215) — and they gate the lowered 5.0 cm (2a) option.
  • Growth criterion tightened: ≥0.5 cm/yr "has been, and remains" an indication; 2022 adds ≥0.3 cm/yr sustained over 2 years as Class 1 (Isselbacher 2022, PMID 36322642).
  • Indexed criteria formalized: ASI (Davies 2006, PMID 16368358), AHI (Zafar 2018, PMID 29395211), and area/height (Svensson 2002, PMID 11828302) enter the recommendation tables at 2a–2b rather than living only in discussion text.
  • Genotype-specific management expands (gene-stratified thresholds, cascade testing Class 1, family imaging screening Class 1) (Isselbacher 2022, PMID 36322642).
  • Emphasis on shared decision-making (borderline diameters, VSRR vs composite, pregnancy) and on sex-specific gaps ("more studies are required... in women") (Isselbacher 2022, PMID 36322642).
  • Per its own abstract, the 2022 document consolidated and updated recommendations from the 2010 thoracic-aortic, peripheral-artery, and BAV documents with "new evidence" and added emphasis on volume and multidisciplinary expertise (Isselbacher 2022, PMID 36322642).

Specific numeric deltas against 2010/2014 (e.g., what 2010 said for genetic-syndrome thresholds) are not reproduced here: the 2010 and 2014 full texts were not retrievable for verification in this session — only their identities were confirmed (PMID 20233780; PMID 25173340). [unverified beyond document identity]

2024 EACTS/STS guideline (thresholds verified from full text)

EACTS and STS jointly issued "Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ" (Czerny et al.), published February 2024 in EJCTS (PMID 38408364) and Ann Thorac Surg (2024;118:5-115; PMID 38416090), with a 2024 clinical-cases companion (PMID 39196761). The framing of the aorta as an "organ" — diagnosed and treated as an integrated whole rather than segment by segment — is the headline conceptual move; the full text (retrieved via EJCTS/OUP this session) confirms substantive operative divergence from ACC/AHA (PMID 38408364).

Root and ascending aorta (EACTS/STS Recommendation Table 12)

Trigger Class LoE
Root or tubular ascending aneurysm ≥55 mm (TAV or BAV) I B
BAV aortopathy with "root phenotype" ≥50 mm I B
TAV "root phenotype" ≥50 mm, low surgical risk IIa B
"Ascending phenotype" dilatation >52 mm, low surgical risk (TAV and BAV) IIa C
BAV "ascending phenotype" ≥50 mm, low risk, + ≥1 risk factor: age <50, height <1.69 m, ascending length >11 cm, growth >3 mm/yr, family history of acute aortic syndrome, coarctation, refractory hypertension, shared decision, concomitant non-aortic-valve cardiac surgery IIa C
Non-syndromic TAV "ascending phenotype" ≥50 mm, low risk, + ≥1 risk factor (age <50, height <1.69 m, length >11 cm, growth >3 mm/yr, refractory hypertension, shared decision) IIb C
TAV root/ascending ≥50 mm during non-aortic-valve cardiac surgery IIa C
Root/ascending ≥45 mm during aortic valve surgery IIa C
Root ≥45 mm when the ascending aorta is being replaced IIa C
Concomitant root below 45 mm: young age + family history of type A dissection or known HTAD, individualized IIb C

Verified footnotes: the diameter–risk curve is re-read with its first hinge point at 52.5 mm (predissection tubular diameters run 18–32% smaller than measured after dissection), and the 52.5/53-mm threshold corresponds to acute-aortic-event risk rising from <1% to 4–5%, with predicted perioperative mortality <3% justifying surgery; for a 1.50-m patient, 50 mm corresponds to ~13 cm²/m area/height (≈53 mm at 1.69 m); length is measured by centerline from the annular plane to the brachiocephalic trunk (PMID 38408364).

Other segments and genotypes (Tables 13–18, selected)

Item Class LoE
Ascending aortic length >110 mm as a risk factor for aortic events when indicating elective surgery IIa B
Height nomograms for individuals of small body size IIa B
Symptomatic ascending aneurysm: surgery almost independently of size IIa C
Asymptomatic isolated arch aneurysm ≥55 mm IIa B
Chronic aortic dissection ≥55 mm (ascending not involved) I B
Descending aneurysm ≥55 mm I C
Descending <55 mm with high-risk features IIa C
Marfan root/ascending ≥50 mm I B
Marfan ≥45 mm + high-risk features (family history of dissection; growth >0.3 cm/yr; diffuse root+ascending dilation; marked vertebral arterial tortuosity) IIa B
Loeys-Dietz TGFBR1 or TGFBR2: root/ascending ≥45 mm I C
TGFBR2 + high-risk features (e.g., R528H/C; women with small body size; severe extra-aortic features; family history of dissection; growth >0.3 cm/yr): ≥40 mm IIa C
TGFBR1 + high-risk features: ≥40 mm IIb C
SMAD3 ≥45 mm IIa C
TGFB3 ≥50 mm; SMAD2 or TGFB2 ≥45 mm; TGFBR1/TGFBR2/SMAD3 intact arch/descending/abdominal ≥45 mm IIb C
nsHTAD ACTA2 root/ascending ≥45 mm IIa C
ACTA2 + high-risk features ≥42 mm; PRKG1 ≥45 mm (≥40 mm with high-risk features); MYLK or MYH11 ≥45 mm IIb C

(All rows: Czerny 2024, PMID 38408364.)

Where EACTS/STS 2024 and ACC/AHA 2022 actually differ

  • Gate for sub-5.5 surgery: ACC/AHA conditions 5.0 cm on "experienced surgeons in a Multidisciplinary Aortic Team" (2a B-NR); EACTS/STS conditions on low operative risk plus named patient risk factors — including height <1.69 m and ascending length >11 cm — with no team gate in the threshold rows (hybrid/endovascular arch repair does carry a Class I "experienced centres with adequate open and endovascular volume" requirement) (PMID 38408364; Isselbacher 2022, PMID 36322642).
  • Aortic length: formally adopted as a risk criterion (>11 cm, IIa B — the Wu 2019 centerline measure, PMID 31526537), versus ACC/AHA's "retrospectively promising, but none has been prospectively validated" (Isselbacher 2022, PMID 36322642).
  • Phenotype-split thresholds: root vs ascending phenotype carry different numbers; BAV root phenotype reaches Class I at 50 mm — more aggressive than ACC/AHA's BAV 2a at 5.0–5.4 cm + risk factor (PMID 38408364).
  • Per-gene thresholds: broadly concordant with ACC/AHA's construct (TGFBR1/2 anchored at 45 mm, modulated to 40; ACTA2/MYLK/MYH11 at 45) and — unlike the ACC/AHA table in the retrievable renderings — verifiable per gene with explicit class/level (PMID 38408364).
  • Concomitant replacement at valve surgery: both documents land at ≥45 mm (ACC/AHA 2a B-NR for BAV at surgical AVR; EACTS/STS IIa C for any aortic valve surgery) (PMID 38408364; Isselbacher 2022, PMID 36322642).

Where guidelines disagree or admit uncertainty

  • 5.0 vs 5.5 cm: 2022 ACC/AHA keeps 5.5 as Class 1 but blesses 5.0 (2a) only at experienced MAT centers — a compromise between the size-paradox data (Pape 2007, PMID 17709637; Paruchuri 2015, PMID 25997607) and the absence of randomized proof, explicitly awaiting TITAN:SvS (NCT03536312) (Isselbacher 2022, PMID 36322642).
  • Indexed vs absolute size: indexed criteria carry only 2a–2b endorsement despite repeatedly outperforming raw diameter in cohorts (Davies 2006, PMID 16368358; Zafar 2018, PMID 29395211) — "none has been prospectively validated" (Isselbacher 2022, PMID 36322642).
  • Women: the guideline concedes current thresholds may underserve women and calls for sex-specific research; no female-specific diameter exists in any document (Isselbacher 2022, PMID 36322642; Nienaber 2004, PMID 15197151).
  • Fluoroquinolones: association acknowledged only as a research gap — no avoidance recommendation, reflecting the unresolved confounding debate (Isselbacher 2022, PMID 36322642; Gopalakrishnan 2020, PMID 32897307).
  • Exercise: restrictions are C-EO expert opinion; the guideline states outright that evidence on exercise and long-term aortic risk is lacking (Isselbacher 2022, PMID 36322642).
  • PEARS: absent from the US guideline despite ~700 implants in Europe/Commonwealth centers (Treasure 2022, PMID 36094493) — a genuine transatlantic practice divergence.

Open questions

  • Will TITAN:SvS (NCT03536312) validate or refute the 5.0 cm experienced-center pathway — and if positive, does 5.5 cm survive as the Class 1 line? (Isselbacher 2022, PMID 36322642).
  • Can any guideline recommendation for operative thresholds ever exceed LOE B-NR, given the ethics and logistics of randomizing large aneurysms? (Isselbacher 2022, PMID 36322642; Davies 2002, PMID 11834007).
  • The 2024 EACTS/STS and 2022 ACC/AHA constructs verifiably diverge (risk-factor-modified 50 mm + a formal length criterion vs the MAT-gated 5.0 cm; see the EACTS/STS section above) — which document should a given center follow, and will either construct ever be tested against outcomes? (PMID 38408364; Isselbacher 2022, PMID 36322642).
  • Should indexed size (AHI/area-height) replace absolute diameter as the primary criterion for short and tall patients, as cohort discrimination suggests? (Zafar 2018, PMID 29395211; Isselbacher 2022, PMID 36322642).
  • How should "experienced Multidisciplinary Aortic Team" be audited in practice — is the ≥30–40 procedures/yr cut (Hughes 2013, PMID 22306215) the right dividing line for entrusting 5.0 cm surgery?

References

  1. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. Circulation. 2022;146:e334-e482. PMID 36322642. doi:10.1161/CIR.0000000000001106
  2. Isselbacher EM, Preventza O, Hamilton Black J, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease. J Am Coll Cardiol. 2022;80:e223-e393. PMID 36334952. doi:10.1016/j.jacc.2022.08.004
  3. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. Circulation. 2010;121:e266-e369. PMID 20233780. doi:10.1161/CIR.0b013e3181d4739e
  4. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35:2873-2926. PMID 25173340. doi:10.1093/eurheartj/ehu281
  5. Czerny M, Grabenwöger M, Berger T, et al. EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Eur J Cardiothorac Surg. 2024;65(2):ezad426. PMID 38408364. doi:10.1093/ejcts/ezad426. (Full text retrieved via EJCTS/OUP and verified 2026-08-28.)
  6. Czerny M, Grabenwöger M, Berger T, et al. EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Ann Thorac Surg. 2024;118:5-115. PMID 38416090. doi:10.1016/j.athoracsur.2024.01.021
  7. Czerny M, Berger T, Della Corte A, et al. Clinical cases referring to the 2023 EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ. Eur J Cardiothorac Surg. 2024;66(3):ezae294. PMID 39196761. doi:10.1093/ejcts/ezae294
  8. Goldstein SA, Evangelista A, Abbara S, et al. Multimodality imaging of diseases of the thoracic aorta in adults (ASE/EACVI). J Am Soc Echocardiogr. 2015;28:119-182. PMID 25623219. doi:10.1016/j.echo.2014.11.015
  9. Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? J Thorac Cardiovasc Surg. 1997;113:476-491. PMID 9081092. doi:10.1016/S0022-5223(97)70360-X
  10. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms. Ann Thorac Surg. 2002;73:17-27. PMID 11834007. doi:10.1016/s0003-4975(01)03236-2
  11. Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg. 2006;81:169-177. PMID 16368358. doi:10.1016/j.athoracsur.2005.06.026
  12. Zafar MA, Li Y, Rizzo JA, et al. Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm. J Thorac Cardiovasc Surg. 2018;155:1938-1950. PMID 29395211. doi:10.1016/j.jtcvs.2017.10.140
  13. Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg. 2002;123:360-361. PMID 11828302. doi:10.1067/mtc.2002.118497
  14. Pape LA, Tsai TT, Isselbacher EM, et al. Aortic diameter ≥5.5 cm is not a good predictor of type A aortic dissection (IRAD). Circulation. 2007;116:1120-1127. PMID 17709637. doi:10.1161/CIRCULATIONAHA.107.702720
  15. Paruchuri V, Salhab KF, Kuzmik G, et al. Aortic size distribution in the general population: explaining the size paradox in aortic dissection. Cardiology. 2015;131:265-272. PMID 25997607. doi:10.1159/000381281
  16. Pitcher A, Spata E, Emberson J, et al. Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis. Lancet. 2022;400:822-831. PMID 36049495. doi:10.1016/S0140-6736(22)01534-3
  17. Coselli JS, LeMaire SA, Köksoy C, et al. Cerebrospinal fluid drainage reduces paraplegia after thoracoabdominal aortic aneurysm repair: a randomized clinical trial. J Vasc Surg. 2002;35:631-639. PMID 11932655. doi:10.1067/mva.2002.122024
  18. Hughes GC, Zhao Y, Rankin JS, et al. Effects of institutional volumes on operative outcomes for aortic root replacement in North America. J Thorac Cardiovasc Surg. 2013;145:166-170. PMID 22306215. doi:10.1016/j.jtcvs.2011.10.094
  19. Nienaber CA, Fattori R, Mehta RH, et al. Gender-related differences in acute aortic dissection. Circulation. 2004;109:3014-3021. PMID 15197151. doi:10.1161/01.CIR.0000130644.78677.2C
  20. Gopalakrishnan C, Bykov K, Fischer MA, et al. Association of fluoroquinolones with the risk of aortic aneurysm or aortic dissection. JAMA Intern Med. 2020;180:1596-1605. PMID 32897307. doi:10.1001/jamainternmed.2020.4199
  21. Treasure T, Austin C, Kenny LA, Pepper J. Personalized external aortic root support in aneurysm disease. Curr Opin Cardiol. 2022;37:454-458. PMID 36094493. doi:10.1097/HCO.0000000000000990
  22. Treatment in Thoracic Aortic Aneurysm: Surgery versus Surveillance (TITAN:SvS). ClinicalTrials.gov NCT03536312 (recruiting; verified 2026-08-27).